Could not find a Solr index corresponding to your website and environment. To fix this problem, please read our documentation.
Could not find a Solr index corresponding to your website and environment. To fix this problem, please read our documentation.
Deadline 16 March 2022
UK Health Security Agency, Porton Down, UK
The TB Vaccine Evaluation Group uses the non-human primate (NHP) model to assess the safety, efficacy and immunogenicity of a range of novel vaccines and therapeutics to protect against and treat Tuberculosis, a disease that was responsible for 1.4 million deaths in 2019.
You will be involved in the analysis of blood samples to measure the mycobacteria-specific cellular immune response in response to vaccination and/or infection at ACDP Containment Levels 2 & 3 using a range of advanced immunoassays including; the ELISPOT assay, flow cytometry and multiplex bead array technology.
